Evommune posted a Q2 net loss of USD 32.25 million, widening from USD 13.57 million a year earlier.
R&D expense rose 34.49% to USD 26.41 million, while G&A expense more than doubled to USD 8.48 million.
Revenue was nil, versus nil in the prior-year quarter.
Cash position and pipeline timing
Cash, cash equivalents and investments totaled USD 288 million at June 30, up from USD 216.7 million at Dec. 31.
Evommune expects EVO756 atopic dermatitis Phase 2b top-line data in September 2026; migraine prophylaxis Phase 2b top-line data is anticipated in 2027.
EVMN•
